(1S,2S)-Bortezomib

• CAT Number: R017652
• CAS Number: 1132709-14-8
• Molecular Formula: C19H25BN4O4
• Molecular Weight: 384.24
• Purity: ≥95%
• Synonyms: B-[(1S)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic Acid
• Storage: -20°C
• IUPAC Name: [(1S)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
• InChI: InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17+/m0/s1
• InChIKey: GXJABQQUPOEUTA-DOTOQJQBSA-N
• SMILES: B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O

(1S,2S)-Bortezomib（Cat No.:R017652）is the enantiomer of Bortezomib, an important anticancer drug. Bortezomib is a potent, reversible, and selective proteasome inhibitor that disrupts the cell cycle, induces apoptosis, and inhibits nuclear factor NF-κB. It exerts its anticancer effects by targeting threonine residues and potently inhibiting the 20S proteasome (Ki of 0.6 nM). Bortezomib was the first proteasome inhibitor approved for use in humans and has been successfully used in the treatment of multiple myeloma and certain types of lymphoma.